Published in PLoS One on August 09, 2013
Kinome profiling reveals breast cancer heterogeneity and identifies targeted therapeutic opportunities for triple negative breast cancer. Oncotarget (2014) 0.91
Inhibition of tobacco smoke-induced bladder MAPK activation and epithelial-mesenchymal transition in mice by curcumin. Int J Clin Exp Pathol (2015) 0.87
MEK5/ERK5 signaling inhibition increases colon cancer cell sensitivity to 5-fluorouracil through a p53-dependent mechanism. Oncotarget (2016) 0.79
MAPK7 Regulates EMT Features and Modulates the Generation of CTCs. Mol Cancer Res (2015) 0.77
ERK5 negatively regulates tobacco smoke-induced pulmonary epithelial-mesenchymal transition. Oncotarget (2015) 0.77
EGCG Suppresses ERK5 Activation to Reverse Tobacco Smoke-Triggered Gastric Epithelial-Mesenchymal Transition in BALB/c Mice. Nutrients (2016) 0.75
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell (2006) 27.36
Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer (2009) 5.89
NF-kappaB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2. Oncogene (2006) 3.91
Carcinoma invasion and metastasis: a role for epithelial-mesenchymal transition? Cancer Res (2005) 3.78
Activation of the protein kinase ERK5/BMK1 by receptor tyrosine kinases. Identification and characterization of a signaling pathway to the nucleus. J Biol Chem (1999) 3.42
Twist regulates cytokine gene expression through a negative feedback loop that represses NF-kappaB activity. Cell (2003) 3.40
Hyperexpression of mitogen-activated protein kinase in human breast cancer. J Clin Invest (1997) 3.26
Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene (2003) 2.82
Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res (2006) 2.63
Bmk1/Erk5 is required for cell proliferation induced by epidermal growth factor. Nature (1998) 2.62
Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors. Cancer Res (2006) 2.46
Reversal of the estrogen receptor negative phenotype in breast cancer and restoration of antiestrogen response. Clin Cancer Res (2007) 2.38
Regulation of cellular functions by the ERK5 signalling pathway. Cell Signal (2006) 1.98
Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells. Mol Endocrinol (2001) 1.96
MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion. Oncogene (2003) 1.83
Formation of an IKKalpha-dependent transcription complex is required for estrogen receptor-mediated gene activation. Mol Cell (2005) 1.82
Evaluation of potential Stat3-regulated genes in human breast cancer. Biochem Biophys Res Commun (2005) 1.76
Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein. Cancer Cell (2010) 1.72
Molecular cloning of mouse ERK5/BMK1 splice variants and characterization of ERK5 functional domains. J Biol Chem (2001) 1.58
Differential regulation of mitogen-activated protein kinases ERK1/2 and ERK5 by neurotrophins, neuronal activity, and cAMP in neurons. J Neurosci (2001) 1.52
Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance. J Clin Oncol (2008) 1.47
Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer. Cancer Res (2010) 1.45
Key signalling nodes in mammary gland development and cancer. Mitogen-activated protein kinase signalling in experimental models of breast cancer progression and in mammary gland development. Breast Cancer Res (2009) 1.40
MEK5/ERK5 pathway: the first fifteen years. Biochim Biophys Acta (2011) 1.39
Elevated expression levels of NCOA3, TOP1, and TFAP2C in breast tumors as predictors of poor prognosis. Cancer (2003) 1.35
Proteomic analysis of tumor necrosis factor-alpha resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype. Breast Cancer Res (2008) 1.35
Expression of Erk5 in early stage breast cancer and association with disease free survival identifies this kinase as a potential therapeutic target. PLoS One (2009) 1.35
Differences in susceptibility to tumor necrosis factor alpha-induced apoptosis among MCF-7 breast cancer cell variants. Cancer Res (1998) 1.32
Identification of ERF-1 as a member of the AP2 transcription factor family. Proc Natl Acad Sci U S A (1997) 1.31
ERK5 and ERK2 cooperate to regulate NF-kappaB and cell transformation. J Biol Chem (2000) 1.30
Antiestrogenic effects of the novel sphingosine kinase-2 inhibitor ABC294640. Endocrinology (2010) 1.29
Computational analysis of microRNA profiles and their target genes suggests significant involvement in breast cancer antiestrogen resistance. Bioinformatics (2008) 1.27
Identification of mitogen-activated protein kinase kinase as a chemoresistant pathway in MCF-7 cells by using gene expression microarray. Surgery (2002) 1.27
TFAP2C controls hormone response in breast cancer cells through multiple pathways of estrogen signaling. Cancer Res (2007) 1.19
AP-2 regulates the transcription of estrogen receptor (ER)-beta by acting through a methylation hotspot of the 0N promoter in prostate cancer cells. Oncogene (2007) 1.16
ER re-expression and re-sensitization to endocrine therapies in ER-negative breast cancers. J Mammary Gland Biol Neoplasia (2009) 1.14
Overexpression of TFAP2C in invasive breast cancer correlates with a poorer response to anti-hormone therapy and reduced patient survival. J Pathol (2009) 1.12
Effects of human mesenchymal stem cells on ER-positive human breast carcinoma cells mediated through ER-SDF-1/CXCR4 crosstalk. Mol Cancer (2010) 1.08
The unique C-terminal tail of the mitogen-activated protein kinase ERK5 regulates its activation and nuclear shuttling. J Biol Chem (2004) 1.08
Effect of levonorgestrel IUD and oral medroxyprogesterone acetate on glandular and stromal progesterone receptors (PRA and PRB), and estrogen receptors (ER-alpha and ER-beta) in human endometrial hyperplasia. Gynecol Oncol (2005) 1.06
Role of PELP1/MNAR signaling in ovarian tumorigenesis. Cancer Res (2008) 1.05
Neuroprotective role of ERK1/2 and ERK5 in a dopaminergic cell line under basal conditions and in response to oxidative stress. J Neurosci Res (2006) 1.04
TNF-alpha enhances estrogen-induced cell proliferation of estrogen-dependent breast tumor cells through a complex containing nuclear factor-kappa B. Oncogene (2006) 1.04
Role of extracellular signal regulated kinase 5 in neuronal survival. Eur J Biochem (2004) 1.02
Differential role of MEK5alpha and MEK5beta in BMK1/ERK5 activation. J Biol Chem (2003) 1.01
Breast cancer progression with a Twist. Nat Med (2004) 0.98
Design, synthesis, and biological activity of a family of novel ceramide analogues in chemoresistant breast cancer cells. J Med Chem (2009) 0.98
Phosphotyrosine-specific phosphatase PTP-SL regulates the ERK5 signaling pathway. J Biol Chem (2002) 0.95
AKT regulation of estrogen receptor beta transcriptional activity in breast cancer. Cancer Res (2006) 0.93
Immunohistochemical assay for oestrogen receptors in paraffin wax sections of breast carcinoma using a new monoclonal antibody. J Pathol (1996) 0.90
Molecular effects of soy phytoalexin glyceollins in human prostate cancer cells LNCaP. Mol Carcinog (2009) 0.89
PKC-mediated survival signaling in breast carcinoma cells: a role for MEK1-AP1 signaling. Int J Oncol (2005) 0.82
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med (2003) 7.35
Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res (2008) 6.38
Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer (2011) 5.28
Autophagy regulates adipose mass and differentiation in mice. J Clin Invest (2009) 3.95
MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J Biol Chem (2010) 2.85
Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res (2006) 2.63
Retracted Novel role of gp91(phox)-containing NAD(P)H oxidase in vascular endothelial growth factor-induced signaling and angiogenesis. Circ Res (2002) 2.56
Combinatorial analysis of transcription factor partners reveals recruitment of c-MYC to estrogen receptor-alpha responsive promoters. Mol Cell (2006) 2.48
Predisposition to atypical teratoid/rhabdoid tumor due to an inherited INI1 mutation. Pediatr Blood Cancer (2006) 2.48
EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med (2011) 2.46
The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by functioning as a STAT5A nuclear chaperone. J Cell Biol (2004) 2.41
Bone marrow is a reservoir for CD4+CD25+ regulatory T cells that traffic through CXCL12/CXCR4 signals. Cancer Res (2004) 2.28
Inhibition of MCL-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy. Cancer Biol Ther (2009) 2.21
Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells. Cancer Res (2011) 2.13
MicroRNA and mRNA integrated analysis (MMIA): a web tool for examining biological functions of microRNA expression. Nucleic Acids Res (2009) 2.03
Epithelial progeny of estrogen-exposed breast progenitor cells display a cancer-like methylome. Cancer Res (2008) 1.99
A woman in her 40s with AIDS and lung mass. Chest (2014) 1.99
Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer. Cancer Res (2004) 1.97
MicroRNA cluster 221-222 and estrogen receptor alpha interactions in breast cancer. J Natl Cancer Inst (2010) 1.94
Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer. BMC Med (2011) 1.93
Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin Cancer Res (2002) 1.91
Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. BMC Med Genomics (2009) 1.91
Epigenetic resensitization to platinum in ovarian cancer. Cancer Res (2012) 1.88
Alcohol alters DNA methylation patterns and inhibits neural stem cell differentiation. Alcohol Clin Exp Res (2011) 1.88
Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells. Blood (2010) 1.84
Abrogation of TGF-beta1-induced fibroblast-myofibroblast differentiation by histone deacetylase inhibition. Am J Physiol Lung Cell Mol Physiol (2009) 1.82
Wnt5a regulates directional cell migration and cell proliferation via Ror2-mediated noncanonical pathway in mammalian palate development. Development (2008) 1.74
NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers. Cancer Cell (2013) 1.67
Quantitative assessment of somatosensory-evoked potentials after cardiac arrest in rats: prognostication of functional outcomes. Crit Care Med (2010) 1.66
CHIP (carboxyl terminus of Hsc70-interacting protein) promotes basal and geldanamycin-induced degradation of estrogen receptor-alpha. Mol Endocrinol (2005) 1.66
Harmonin mutations cause mechanotransduction defects in cochlear hair cells. Neuron (2009) 1.63
Research recruitment practices and critically ill patients. A multicenter, cross-sectional study (the Consent Study). Am J Respir Crit Care Med (2013) 1.63
Expression of human equilibrative nucleoside transporter 1 in mouse neurons regulates adenosine levels in physiological and hypoxic-ischemic conditions. J Neurochem (2011) 1.59
Is overtriage associated with increased mortality? Insights from a simulation model of mass casualty trauma care. Disaster Med Public Health Prep (2007) 1.59
BMP4-mediated brown fat-like changes in white adipose tissue alter glucose and energy homeostasis. Proc Natl Acad Sci U S A (2013) 1.55
Prognostic DNA methylation biomarkers in ovarian cancer. Clin Cancer Res (2006) 1.53
Absence of proteinase-activated receptor-1 signaling affords protection from bleomycin-induced lung inflammation and fibrosis. Am J Pathol (2005) 1.53
Alcohol exposure alters DNA methylation profiles in mouse embryos at early neurulation. Epigenetics (2009) 1.53
EGFR signaling in breast cancer: bad to the bone. Semin Cell Dev Biol (2010) 1.52
Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat. Breast Cancer Res (2012) 1.51
Identifying estrogen receptor alpha target genes using integrated computational genomics and chromatin immunoprecipitation microarray. Nucleic Acids Res (2004) 1.50
Prenatal bisphenol a exposure and child behavior in an inner-city cohort. Environ Health Perspect (2012) 1.50
Impulse oscillometry in adults with bronchiectasis. Ann Am Thorac Soc (2015) 1.49
Minireview: epigenetic changes in ovarian cancer. Endocrinology (2009) 1.49
A Poisson mixture model to identify changes in RNA polymerase II binding quantity using high-throughput sequencing technology. BMC Genomics (2008) 1.49
Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer. Cancer Res (2010) 1.45
Nonbeneficial treatment Canada: definitions, causes, and potential solutions from the perspective of healthcare practitioners*. Crit Care Med (2015) 1.45
Gene expression profiling of nasopharyngeal carcinoma reveals the abnormally regulated Wnt signaling pathway. Hum Pathol (2006) 1.44
Duration of Antimicrobial Treatment for Bacteremia in Canadian Critically Ill Patients. Crit Care Med (2016) 1.44
Differences in gastric carcinoma microenvironment stratify according to EBV infection intensity: implications for possible immune adjuvant therapy. PLoS Pathog (2013) 1.43
DTNBP1, a schizophrenia susceptibility gene, affects kinetics of transmitter release. J Cell Biol (2008) 1.42
Oncogenic HER2{Delta}16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors. Carcinogenesis (2010) 1.42
Absence of functional EpoR expression in human tumor cell lines. Blood (2010) 1.41
The epigenetics of ovarian cancer drug resistance and resensitization. Am J Obstet Gynecol (2004) 1.41
miR-216b suppresses tumor growth and invasion by targeting KRAS in nasopharyngeal carcinoma. J Cell Sci (2011) 1.41
Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer. Mol Cancer Ther (2005) 1.40
A mouse model for nonsyndromic deafness (DFNB12) links hearing loss to defects in tip links of mechanosensory hair cells. Proc Natl Acad Sci U S A (2009) 1.39
MEK5/ERK5 pathway: the first fifteen years. Biochim Biophys Acta (2011) 1.39
Triple analysis of the cancer epigenome: an integrated microarray system for assessing gene expression, DNA methylation, and histone acetylation. Cancer Res (2003) 1.38
Patients with spina bifida and bladder cancer: atypical presentation, advanced stage and poor survival. J Urol (2007) 1.38
Circulating miR-17, miR-20a, miR-29c, and miR-223 combined as non-invasive biomarkers in nasopharyngeal carcinoma. PLoS One (2012) 1.37
Fulvestrant (ICI 182,780)-dependent interacting proteins mediate immobilization and degradation of estrogen receptor-alpha. J Biol Chem (2006) 1.35
Proteomic analysis of tumor necrosis factor-alpha resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype. Breast Cancer Res (2008) 1.35
A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer. Cancer (2010) 1.34
Modulation of BMP signaling by Noggin is required for the maintenance of palatal epithelial integrity during palatogenesis. Dev Biol (2010) 1.34
The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells. Blood (2007) 1.33
GPIHBP1 stabilizes lipoprotein lipase and prevents its inhibition by angiopoietin-like 3 and angiopoietin-like 4. J Lipid Res (2009) 1.33
Antiestrogenic glyceollins suppress human breast and ovarian carcinoma tumorigenesis. Clin Cancer Res (2006) 1.31
MicroRNA-192 targeting retinoblastoma 1 inhibits cell proliferation and induces cell apoptosis in lung cancer cells. Nucleic Acids Res (2011) 1.30
The NEDD8 pathway is required for proteasome-mediated degradation of human estrogen receptor (ER)-alpha and essential for the antiproliferative activity of ICI 182,780 in ERalpha-positive breast cancer cells. Mol Endocrinol (2002) 1.30
Histone deacetylase 6-mediated selective autophagy regulates COPD-associated cilia dysfunction. J Clin Invest (2013) 1.29
Antiestrogenic effects of the novel sphingosine kinase-2 inhibitor ABC294640. Endocrinology (2010) 1.29
Adult human mesenchymal stem cells enhance breast tumorigenesis and promote hormone independence. Breast Cancer Res Treat (2009) 1.29
4,4'-Bipyridinium 1,4-phenyl-ene-diacetate. Acta Crystallogr Sect E Struct Rep Online (2009) 1.29
Novel ceramide analogs as potential chemotherapeutic agents in breast cancer. J Pharmacol Exp Ther (2004) 1.28
Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo. Cancer Biol Ther (2010) 1.28
BRD7, a novel bromodomain gene, inhibits G1-S progression by transcriptionally regulating some important molecules involved in ras/MEK/ERK and Rb/E2F pathways. J Cell Physiol (2004) 1.27